Welcome to our dedicated page for Abeona Therapeut news (Ticker: ABEO), a resource for investors and traders seeking the latest updates and insights on Abeona Therapeut stock.
Abeona Therapeutics Inc. (Nasdaq: ABEO) is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, with a primary focus on recessive dystrophic epidermolysis bullosa (RDEB)ZEVASKYN® (prademagene zamikeracel), which Abeona describes as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with RDEB.
On this page, readers can follow ABEO news related to ZEVASKYN’s commercial rollout, including activation of new Qualified Treatment Centers, initial patient treatments, and updates on manufacturing and product release processes at the company’s cell and gene therapy cGMP facility in Cleveland, Ohio. Press releases also cover developments in reimbursement and market access, such as the assignment of a permanent HCPCS J-code (J3389) by the Centers for Medicare and Medicaid Services (CMS) and coverage decisions by commercial health plans.
Abeona’s news flow additionally features corporate and pipeline updates, including quarterly financial results, participation in investor conferences, and progress in its AAV-based gene therapy programs, such as the ABO-503 program for X-linked retinoschisis (XLRS) selected for the FDA’s Rare Disease Endpoint Advancement Pilot Program. Management appointments and employee equity inducement grants under Nasdaq Listing Rule 5635(c)(4) are also regular topics.
Investors, clinicians, and other stakeholders can use this ABEO news feed to review the company’s latest disclosures on commercial performance indicators, regulatory and payer milestones, treatment site expansion, and strategic pipeline initiatives in gene therapy.
Abeona Therapeutics (Nasdaq: ABEO) announced the publication of Phase 3 VIITAL study results in The Lancet for ZEVASKYN™, their FDA-approved gene therapy for treating RDEB wounds. The study demonstrated significant efficacy with 81% of treated wounds showing ≥50% healing compared to 16% in control wounds after 24 weeks.
The trial involved 11 patients with 43 pairs of large chronic wounds. Key results showed 65% of treated wounds achieved ≥75% healing versus 7% of control wounds. Patients experienced significant pain reduction (-3.1 in treated vs -0.9 in control wounds). The therapy demonstrated a favorable safety profile with no serious treatment-related adverse events.
ZEVASKYN is the first and only FDA-approved autologous cell-based gene therapy for treating recessive dystrophic epidermolysis bullosa (RDEB) wounds. The company expects to treat its first commercial patient in Q3 2025.
Abeona Therapeutics (NASDAQ: ABEO) and Lurie Children's Hospital announced the activation of the first Qualified Treatment Center (QTC) for ZEVASKYN, a groundbreaking gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN, recently FDA-approved on April 29, 2025, is the first and only autologous cell-based gene therapy for RDEB wounds treatment with a single application.
Lurie Children's, a top-ranked hospital caring for over 150 epidermolysis bullosa patients, will begin patient identification with treatments expected to start in Q3 2025. The first patient is scheduled for biopsy in July 2025 and treatment in August 2025. To support patient access, Abeona has launched Abeona Assist, a comprehensive support program offering insurance benefits guidance, financial assistance, and travel logistics support.
Abeona Therapeutics (NASDAQ: ABEO) has announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $155 million. The company received the PRV following FDA approval of ZEVASKYN™ (prademagene zamikeracel) on April 28, 2025. According to CFO Joe Vazzano, the proceeds will provide sufficient cash for over two years of operating expenses without requiring additional capital, excluding ZEVASKYN sales revenue.
ZEVASKYN is scheduled to become available for patient treatment in Q3 2025, with the company projecting profitability by early 2026. The PRV sale transaction remains subject to standard closing conditions, including Hart-Scott Rodino Antitrust Improvements Act waiting period expiration. Stifel led the financial advisory role, with Jefferies also serving as advisor.
Abeona Therapeutics (NASDAQ: ABEO) has granted equity awards to seven new non-executive employees as inducement for their employment. The awards, approved by the Compensation Committee on April 30, 2025, consist of a total of 21,500 restricted shares of Abeona common stock. The shares will vest in three equal annual installments, with full vesting occurring on the third anniversary of the Grant Date, contingent upon continued employment with the company.
Abeona Therapeutics has received FDA approval for ZEVASKYN, the first cell-based gene therapy for treating Recessive Dystrophic Epidermolysis Bullosa (RDEB). The therapy, approved for both adult and pediatric patients, demonstrated significant results in the Phase 3 VIITAL study:
- 81% of treated wounds showed 50% or more healing after 6 months
- Single application provides long-term wound healing and pain reduction
- Treatment will be available through Qualified Treatment Centers in Q3 2025
The therapy uses patients' own skin cells, modified to produce Type VII collagen, treating a condition that causes severe blistering and wounds covering up to 80% of patients' bodies. The FDA granted a Rare Pediatric Disease Priority Review Voucher with the approval. Abeona Assist program will provide patient support, including insurance and logistics assistance.
Abeona Therapeutics (Nasdaq: ABEO) has announced new equity awards for six recently hired non-executive employees. The awards, approved under Nasdaq Listing Rule 5635(c)(4) by the Compensation Committee on March 31, 2025, consist of a total of 23,700 restricted shares of Abeona common stock.
The restricted stock awards feature a three-year vesting schedule, with one-third of the shares vesting annually on each anniversary of the Grant Date. Full vesting will occur on the third anniversary, contingent upon continued employment with Abeona.